aana glp-1 guidelines Indications for GLP-1/GIP RA Summary Sheet and Beyond! View of GLP-1 receptor agonists

Determining the true incidence of gastroparesis associated with GLP-1 receptor agonist use presents significant methodologic challenges

M., Cummings, N., Larson, L

Clinical trials have yielded mixed results: several studies, including a phase II trial of NLY01, failed to meet primary endpoints for motor progression, with only modest or nonsignificant effects overall [37,38]

market is still dominated by innovators like Novo Nordisk and Eli Lilly Patent protections and regulatory barriers delay generic entry Sun Pharma is focusing on future entry through innovation and specialty drugs However, this is expected to change in the coming years as patents expire and biosimilars gain approvals